Protective Anti-Müllerian Hormone Levels Linked to Ovarian Function in MS
Key Highlights
Medicine · Neurology
A recent study reveals that higher serum levels of anti-Müllerian hormone (AMH) are associated with reduced relapse rates and lower disability accumulation in premenopausal women with multiple sclerosis. Researchers found that women with AMH levels above the median had a 37% lower risk of relapse and a lower risk of confirmed disability worsening over a follow-up period. This finding suggests that ovarian reserve, as measured by AMH, may serve as a clinically actionable proteomic biomarker for disease activity in MS, offering new avenues for integrating endocrine markers with multimodal monitoring strategies including imaging and clinical data.
Novelty: 88%
Rigor: 82%
Significance: 90%
Validity: 79%
Clarity: 92%
Update Your Briefing Preferences
Stay curious. Stay informed —
Science Briefing
Your briefing is personalized based on your selected fields, keywords, and research interests.
